Published on Tue Jun 22 2021

A Case of Autoimmune Hemolytic Anemia Following COVID-19 Messenger Ribonucleic Acid Vaccination.

Sérgio Brito, Nuno Ferreira, Sofia Mateus, Manuela Bernardo, Beatriz Pinto, Ana Lourenço, Fátima Grenho

Autoimmune hemolytic anemia (AIHA) is a condition characterized by the increased destruction of red blood cells. Its clinical presentation is heterogeneous, ranging from asymptomatic to severe forms with fatal outcomes.

1
32
20
Abstract

Autoimmune hemolytic anemia (AIHA) is a condition characterized by the increased destruction of red blood cells (RBCs) mediated by anti-erythrocyte autoantibodies with or without complement activation. Its clinical presentation is heterogeneous, ranging from asymptomatic to severe forms with fatal outcomes, and it can be either idiopathic or secondary to a coexisting disorder. In this report, we present a case of a patient who suffered from acute and severe AIHA after receiving the second dose of the coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccine.